|
Dyadic International, Inc, a global biotechnology company focused on the scalable production of high-value, precision engineered input proteins for non-therapeutic applications in life sciences, food and nutrition, and industrial biotechnology utilizing its proprietary gene expression platforms, announced that, effective in 30 days, it will be doing business as Dyadic Applied BioSolutions, marking a pivotal step in the company’s transition from a research-driven organization to a commercially focused enterprise. The new name and revised visual identity reflect Dyadic’s strategic emphasis on delivering applied biotechnology solutions through its patented and proprietary C1 and Dapibus gene expression platforms.
The rebrand underscores Dyadic’s focus on commercializing high value, non-therapeutic proteins that it believes are essential to life sciences, food, nutritional, and industrial bioprocessing applications. These proteins avoid the regulatory complexity and high costs associated with therapeutic biologics – enabling faster time to revenue, broader market reach, and long-term supply agreements. Recent significant milestones across both food and nutrition as well as fully funded legacy collaborations, discussed below, underscore Dyadic’s strategic shift toward focusing on the commercial execution and market readiness of its C1 and Dapibus platforms.
It reflects the company’s strategic focus on commercializing non-therapeutic proteins and unlocking long-term value from its C1 and Dapibus gene expression platforms.
“As we evolve from licensing our technology in support of therapeutic and vaccine development into a revenue-focused bioprocessing protein platform business, our C1 and Dapibus production platforms remain the engines we expect to drive commercial execution,” said Joe Hazelton, president and chief operating officer of Dyadic. “The progress on our second non-animal dairy enzyme programme – which recently triggered a $250,000 milestone payment – reflects the tangible outcomes of our new focus on commercialization. This rebranding reflects our top priority to deliver high-value input proteins at commercial scale.”
In parallel with its internal commercial focus, Dyadic continues to advance legacy collaborations with key global health partners. Dyadic recently achieved milestones in its partnership with the Gates Foundation, resulting in a second installment of $1.5 million in non-dilutive funding from a $3.0 million grant to further develop low-cost monoclonal antibodies (mAbs) for diseases such as malaria and RSV.
Dyadic remains on track to commercialize its input proteins in 2025, and we believe Dyadic Applied BioSolutions is positioned to deliver sustained revenue and long-term value growth through its production platforms.
|